Baird raised the firm’s price target on Bright Minds (DRUG) to $82 from $75 and keeps an Outperform rating on the shares. The firm updated its model as the BMB-105 Pader-Willi program holds promise.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DRUG: